Cryotherapy is often portrayed as radiofrequency ablation's little brother. But the thermal ablation technique is proving safer and more effective than previously thought, according to several papers presented at the RSNA meeting.
Cryotherapy is often portrayed as radiofrequency ablation's little brother. But the thermal ablation technique is proving safer and more effective than previously thought, according to several papers presented at the RSNA meeting. Cryotherapy can also muscle in on malignancies affecting several organ systems, including the liver, lungs, and kidneys.
Dr. Hussein D. Aoun, a radiologist at Wayne State University Medical Center in Detroit, presented two studies assessing the ability to use cryotherapy to ablate liver and lung tumors. The first evaluated CT-guided treatment of 70 masses with 58 procedures in 47 patients.
Aoun and colleagues found cryotherapy provides a visually reliable and effective treatment alternative to its heat-based brethren. The team successfully treated lesions 3.4 cm in average size, including large masses near blood vessels, with a recurrence rate of 9.7% at two-year follow-up.
The technique is virtually painless and allows use of auxiliary devices unsuitable for RFA, such as balloons, to protect tumor-adjacent organs. It thus proves particularly amenable to patients with anesthesia-related risks and tumors near painful sites, such as the diaphragm or the chest wall, Aoun said.
The second study released data for CT-guided treatment of 56 primary and metastatic lung tumors with 51 procedures in 36 patients. Cryotherapy successfully ablated tumors 3.1 cm in average size, with a two-year recurrence rate of 16.1% for masses.
"Cryotherapy doesn't seem to be as sensitive to tumor size or vessel proximity, because we can actually sculpt the isotherm freezing directly into central structures of almost any area. We learned all this from years of work in the prostate. This is all well-defined science," said coauthor Dr. Peter J. Littrup, a professor of radiology, urology, and radiation oncology at Wayne State.
In another study, Dr. Thomas Atwell presented results on successful percutaneous cryoablation of 59 renal tumors in 58 patients treated from March 2003 to date. Atwell and colleagues placed cryoprobes under ultrasound guidance and monitored ablation results with CT. They achieved a 97% technical success with a mean tumor ablation size of 3.4 cm and only one major complication (hemorrhage). Biopsy confirmed renal cell carcinomas (53%), oncocytic neoplasms (11%), and oncocytomas (28%). Researchers currently have nine-months worth of follow-up for 42 ablated tumors that remain recurrence-free.
Percutaneous ultrasound/CT-guided or monitored cryoablation is a relatively safe method of treating renal tumors in selected patients. Short-term results show promise, but only long-term outcomes will confirm its effectiveness, Atwell said.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.